Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients

Kaya, Ayça; Aydin, Neslihan; Topsever, Pınar; Filiz, Müge; Öztürk, Ali Osman; Dağar, Arslan; Kılınç, Ebru; Ekmekçioğlu, Cem

doi:10.1016/j.biopha.2004.09.006

Cited by 62 publications

(41 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, the combination group lost more weight than the diet alone or orlistat groups, but the amount lost was similar to that for sibutramine alone . Thus, adding orlistat to sibutramine did not significantly enhance weight loss, confirming the observations of Wadden et al (2000) and Kaya et al (2004). f. Dosage and safety considerations.…”

Section: Studies In Childrensupporting

confidence: 67%

Pharmacological Treatment of the Overweight Patient

Bray

Greenway

2007

Pharmacological Reviews

153

116

View full text Add to dashboard Cite

Section: Studies In Childrensupporting

confidence: 67%

Pharmacological Treatment of the Overweight Patient

Bray

Greenway

2007

Pharmacological Reviews

153

116

View full text Add to dashboard Cite

“…Sibutramine's efficacy at causing weight loss is probably owing to an additive effect of serotonin and NE on energy balance (Rowland et al, 2001). Other drug combinations have been studied, but failed to produce an additive, let alone synergistic, effect on energy balance (Kaya et al, 2004).…”

Section: Discussionmentioning

confidence: 99%

Inhibition of Dopamine and Norepinephrine Reuptake Produces Additive Effects on Energy Balance in Lean and Obese Mice

Billes

Cowley

2006

Neuropsychopharmacol

View full text Add to dashboard Cite

Although originally developed as an antidepressant, long-term bupropion (BUP) treatment was recently shown to cause 5-8% weight loss over placebo in clinical trials with obese adults. BUP's antidepressant properties probably stem from its ability to increase extracellular brain dopamine (DA) and norepinephrine (NE) levels by inhibiting their reuptake, although the mechanism of BUP-induced weight loss is unknown. Consequently, the acute effects of DA and NE reuptake inhibition on energy homeostasis were determined by measuring food intake and body weight in mice following peripheral (intraperitoneal (i.p.)) administration of either BUP, a selective DA (GBR12783), or a selective NE (nisoxetine (NIS)) reuptake inhibitor. BUP, GBR12783, and NIS all dose-dependently decreased acute food intake in fasted lean mice. The ability of BUP to decrease food intake was independent of its ability to cause a temporary increase in locomotor activity. The inhibitory effects of acute GBR12783 and NIS on short-term food intake were additive. Subchronic (via miniosmotic pump) administration of GBR12783 and NIS produced a transient nonadditive effect on food intake, but produced an additive reduction in body weight (8-10%). Because obesity can affect catecholaminergic signaling, we determined the effects of i.p. BUP, GBR12783, and NIS on short-term food intake in obese mice. Acute BUP, GBR12783, and NIS dose-dependently reduced acute food intake, and the additive effect of GBR12783 and NIS on acute food intake was preserved in obese mice. These results demonstrate that combined DA and NE reuptake inhibition produces additive effects on energy balance in lean and obese mice on both standard and high-fat diet, providing a foundation for further research on the effects of BUP and similar compounds on energy balance in mice.

show abstract

“…Sibutramine (10-20 mg/day for 12 weeks to 12 months) reduced body weight and BMI more than orlistat (360 mg/day) in three studies in obese patients (total n = 325). [133][134][135] However, in two other studies (total n = 259), sibutramine (10 mg/day given for 12-24 weeks) and orlistat (360 mg/day) induced similar reductions in body weight, BMI, and waist circumference. 136,137 In another study in 115 hypertensive obese patients, sibutramine (10 mg/day given for 12 months) and orlistat (360 mg/day) reduced body weight, BMI, waist circumference and WHR to a similar extent.…”

Section: Comparative Studies With Other Antiobesity Agentsmentioning

confidence: 84%

“…138,140 Combining sibutramine and orlistat (10 mg and 360 mg/day, respectively, for 3-6 months) did not provide additional benefits over sibutramine monotherapy in obese patients. 133,134 Interestingly, a small study in 34 women who had received sibutramine for one year showed that adding orlistat to sibutramine for 16 weeks did not induce further weight loss. 141 In another study in 198 obese patients, combining sibutramine with an experimental selective antagonist of the receptor 5 of the orexigenic neuropeptide Y did not result …”

Section: Comparative Studies With Other Antiobesity Agentsmentioning

confidence: 99%

The use of sibutramine in the management of obesity and related disorders: An update

Tzotzas¹,

Krassas²,

Τζιόμαλος³

et al. 2009

VHRM

View full text Add to dashboard Cite

Aims:To review the major trials that evaluated the efficacy and safety of the use of sibutramine for weight loss and the impact of this agent on obesity-related disorders. Methods and results:The most important articles on sibutramine up to January 2009 were located by a PubMed and Medline search. Sibutramine reduces food intake and body weight more than placebo and has positive effects on the lipid profile (mainly triglycerides and high density lipoprotein cholesterol), glycemic control and inflammatory markers in studies for up to one year. Preliminary studies showed that sibutramine may also improve other obesityassociated disorders such as polycystic ovary syndrome, left ventricular hypertrophy, binge eating disorder and adolescent obesity. The high discontinuation rates and some safety issues mainly due to the increase in blood pressure and pulse rate have to be considered. Additionally, it has not yet been established that treatment with sibutramine will reduce cardiovascular events and total mortality. Conclusions: Sibutramine, in conjunction with lifestyle measures, is a useful drug for reducing body weight and improving associated cardiometabolic risk factors and obesity-related disorders. Studies of longer duration are required to determine the precise indications of the drug, to evaluate safety issues and to assess its efficacy on cardiovascular mortality.

show abstract

Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients

Cited by 62 publications

References 20 publications

Pharmacological Treatment of the Overweight Patient

Pharmacological Treatment of the Overweight Patient

Inhibition of Dopamine and Norepinephrine Reuptake Produces Additive Effects on Energy Balance in Lean and Obese Mice

The use of sibutramine in the management of obesity and related disorders: An update

Contact Info

Product

Resources

About